OBJECTIVES: To investigate the incidence of selected opportunistic infections (OIs) and cancers and the role of a history of tuberculosis (TB) as a risk factor for developing these conditions in HIV-infected patients starting antiretroviral treatment (ART) in Southern Africa. METHODS: Five ART programmes from Zimbabwe, Zambia and South Africa participated. Outcomes were extrapulmonary cryptococcal disease (CM), pneumonia due to Pneumocystis jirovecii (PCP), Kaposi's sarcoma and Non-Hodgkin lymphoma. A history of TB was defined as a TB diagnosis before or at the start of ART. We used Cox models adjusted for age, sex, CD4 cell count at ART start and treatment site, presenting results as adjusted hazard ratios (aHR) with 95% confidence intervals (CI). RESULTS: We analysed data from 175,212 patients enrolled between 2000 and 2010 and identified 702 patients with incident CM (including 205 with a TB history) and 487 with incident PCP (including 179 with a TB history). The incidence per 100 person-years over the first year of ART was 0.48 (95% CI 0.44-0.52) for CM, 0.35 (95% CI 0.32-0.38) for PCP, 0.31 (95% CI 0.29-0.35) for Kaposi's sarcoma and 0.02 (95% CI 0.01-0.03) for Non-Hodgkin lymphoma. A history of TB was associated with cryptococcal disease (aHR 1.28, 95% CI 1.05-1.55) and Pneumocystis jirovecii pneumonia (aHR 1.61, 95% CI 1.27-2.04), but not with Non-Hodgkin lymphoma (aHR 1.09, 95% CI 0.45-2.65) or Kaposi's sarcoma (aHR 1.02, 95% CI 0.81-1.27). CONCLUSIONS: Our study suggests that there may be interactions between different OIs in HIV-infected patients.
OBJECTIVES: To investigate the incidence of selected opportunistic infections (OIs) and cancers and the role of a history of tuberculosis (TB) as a risk factor for developing these conditions in HIV-infectedpatients starting antiretroviral treatment (ART) in Southern Africa. METHODS: Five ART programmes from Zimbabwe, Zambia and South Africa participated. Outcomes were extrapulmonary cryptococcal disease (CM), pneumonia due to Pneumocystis jirovecii (PCP), Kaposi's sarcoma and Non-Hodgkin lymphoma. A history of TB was defined as a TB diagnosis before or at the start of ART. We used Cox models adjusted for age, sex, CD4 cell count at ART start and treatment site, presenting results as adjusted hazard ratios (aHR) with 95% confidence intervals (CI). RESULTS: We analysed data from 175,212 patients enrolled between 2000 and 2010 and identified 702 patients with incident CM (including 205 with a TB history) and 487 with incident PCP (including 179 with a TB history). The incidence per 100 person-years over the first year of ART was 0.48 (95% CI 0.44-0.52) for CM, 0.35 (95% CI 0.32-0.38) for PCP, 0.31 (95% CI 0.29-0.35) for Kaposi's sarcoma and 0.02 (95% CI 0.01-0.03) for Non-Hodgkin lymphoma. A history of TB was associated with cryptococcal disease (aHR 1.28, 95% CI 1.05-1.55) and Pneumocystis jirovecii pneumonia (aHR 1.61, 95% CI 1.27-2.04), but not with Non-Hodgkin lymphoma (aHR 1.09, 95% CI 0.45-2.65) or Kaposi's sarcoma (aHR 1.02, 95% CI 0.81-1.27). CONCLUSIONS: Our study suggests that there may be interactions between different OIs in HIV-infectedpatients.
Authors: Matthias Egger; Didier K Ekouevi; Carolyn Williams; Rita Elias Lyamuya; Henri Mukumbi; Paula Braitstein; Tyler Hartwell; Claire Graber; Benjamin H Chi; Andrew Boulle; François Dabis; Kara Wools-Kaloustian Journal: Int J Epidemiol Date: 2011-05-18 Impact factor: 7.196
Authors: E L Corbett; L Blumberg; G J Churchyard; N Moloi; K Mallory; T Clayton; B G Williams; R E Chaisson; R J Hayes; K M De Cock Journal: Am J Respir Crit Care Med Date: 1999-07 Impact factor: 21.405
Authors: Elizabeth L Corbett; Gavin J Churchyard; Salome Charalambos; Badara Samb; Vicky Moloi; Tim C Clayton; Alison D Grant; Jill Murray; Richard J Hayes; Kevin M De Cock Journal: Clin Infect Dis Date: 2002-04-05 Impact factor: 9.079
Authors: Charles B Holmes; Elena Losina; Rochelle P Walensky; Yazdan Yazdanpanah; Kenneth A Freedberg Journal: Clin Infect Dis Date: 2003-02-17 Impact factor: 9.079
Authors: R S Wallis; M Vjecha; M Amir-Tahmasseb; A Okwera; F Byekwaso; S Nyole; S Kabengera; R D Mugerwa; J J Ellner Journal: J Infect Dis Date: 1993-01 Impact factor: 5.226
Authors: Viviane D Lima; Lillian Lourenço; Benita Yip; Robert S Hogg; Peter Phillips; Julio S G Montaner Journal: Lancet HIV Date: 2015-03 Impact factor: 12.767
Authors: Rachel M Wake; Nazir A Ismail; Shaheed V Omar; Farzana Ismail; Caroline T Tiemessen; Thomas S Harrison; Joseph N Jarvis; Nelesh P Govender Journal: Open Forum Infect Dis Date: 2022-04-17 Impact factor: 4.423
Authors: Lukas Fenner; Andrew Atkinson; Andrew Boulle; Matthew P Fox; Hans Prozesky; Kathrin Zürcher; Marie Ballif; Hansjakob Furrer; Marcel Zwahlen; Mary-Ann Davies; Matthias Egger Journal: J Int AIDS Soc Date: 2017-06-23 Impact factor: 5.396
Authors: Shetty Ravi Dyavar; Timothy M Mykris; Lee C Winchester; Kimberly K Scarsi; Courtney V Fletcher; Anthony T Podany Journal: Sci Rep Date: 2020-07-28 Impact factor: 4.379
Authors: Habib O Ramadhani; John A Bartlett; Nathan M Thielman; Brian W Pence; Stephen M Kimani; Venance P Maro; Mtumwa S Mwako; Lazaro J Masaki; Calvin E Mmbando; Mary G Minja; Eileen S Lirhunde; William C Miller Journal: Open Forum Infect Dis Date: 2016-01-29 Impact factor: 3.835
Authors: Nicky Longley; Joseph Nicholas Jarvis; Graeme Meintjes; Andrew Boulle; Anna Cross; Nicola Kelly; Nelesh P Govender; Linda-Gail Bekker; Robin Wood; Thomas S Harrison Journal: Clin Infect Dis Date: 2015-11-12 Impact factor: 9.079